pdf   xlsx method abbreviations

metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2), atezolizumab alone , meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths (OS) 0.79 [0.70, 0.89]< 10%2 studies (2/-)100.0 %some concernnot evaluable moderatecrucial-
progression or deaths (PFS) 0.96 [0.86, 1.07]< 10%2 studies (2/-)78.7 %some concernnot evaluable moderateimportant-
objective responses (ORR) 1.15 [0.85, 1.55]> 10%2 studies (2/-)81.4 %some concernnot evaluable moderatenon important-

safety endpoints 00

AE (any grade) 0.69 [0.42, 1.13]< 10%2 studies (2/-)93.1 %some concernnot evaluable moderatenon important-
AE (grade 3-4) 0.53 [0.43, 0.65]< 10%2 studies (2/-)100.0 %some concernnot evaluable moderatenon important-
AE leading to death (grade 5) 0.80 [0.40, 1.57]< 10%2 studies (2/-)74.6 %some concernnot evaluable moderatenon important-
AE leading to treatment discontinuation (any grade) 0.45 [0.24, 0.87]< 166%2 studies (2/-)99.2 %some concernnot evaluable moderatenon important-
SAE (any grade) 1.05 [0.64, 1.73]< 10%1 study (1/-)42.1 %NAnot evaluable non important-
SAE (grade 3-4) 1.03 [0.80, 1.31]< 10%1 study (1/-)42.1 %NAnot evaluable non important-
TRAE (any grade) 0.29 [0.22, 0.38]< 10%2 studies (2/-)100.0 %some concernnot evaluable moderatenon important-
TRAE (grade 3-4) 0.23 [0.18, 0.29]< 10%2 studies (2/-)100.0 %some concernnot evaluable moderatenon important-
TRAE leading to death (grade 5) 0.36 [0.05, 2.35]< 10%2 studies (2/-)85.7 %some concernnot evaluable moderatenon important-
TRAE leading to discontinuation (any grade) 0.07 [0.02, 0.29]< 10%1 study (1/-)100.0 %NAnot evaluable non important-

AE (grade 3-4) endpoints 00

Alopecia AE (grade 3-4) 0.47 [0.02, 14.16]< 10%1 study (1/-)66.4 %NAnot evaluable non important-
Anaemia AE (grade 3-4) 0.39 [0.21, 0.73]< 10%1 study (1/-)99.8 %NAnot evaluable non important-
Arthralgia AE (grade 3-4) 2.86 [0.30, 27.54]< 10%1 study (1/-)18.4 %NAnot evaluable non important-
Asthenia AE (grade 3-4) 0.58 [0.24, 1.41]< 10%1 study (1/-)88.6 %NAnot evaluable non important-
Back pain AE (grade 3-4) 1.67 [0.49, 5.73]< 10%1 study (1/-)20.8 %NAnot evaluable non important-
Constipation AE (grade 3-4) 1.90 [0.17, 21.02]< 10%1 study (1/-)30.2 %NAnot evaluable non important-
Cough AE (grade 3-4) 1.90 [0.17, 21.02]< 10%1 study (1/-)30.2 %NAnot evaluable non important-
Decreased appetite AE (grade 3-4) 0.21 [0.04, 0.97]< 10%1 study (1/-)97.7 %NAnot evaluable non important-
Diarrhoea AE (grade 3-4) 0.34 [0.11, 1.08]< 10%1 study (1/-)96.6 %NAnot evaluable non important-
Dysgeusia AE (grade 3-4) 0.95 [0.02, 47.91]< 10%1 study (1/-)51.0 %NAnot evaluable non important-
Dyspnoea AE (grade 3-4) 1.02 [0.49, 2.13]< 10%1 study (1/-)48.2 %NAnot evaluable non important-
Fatigue AE (grade 3-4) 0.69 [0.37, 1.31]< 10%1 study (1/-)87.0 %NAnot evaluable non important-
Febrile neutropenia AE (grade 3-4) 0.01 [0.00, 0.10]< 10%1 study (1/-)100.0 %NAnot evaluable non important-
Myalgia AE (grade 3-4) 0.24 [0.03, 2.12]< 10%1 study (1/-)90.0 %NAnot evaluable non important-
Nausea AE (grade 3-4) 1.90 [0.35, 10.44]< 10%1 study (1/-)23.0 %NAnot evaluable non important-
Neutropenia AE (grade 3-4) 0.03 [0.01, 0.11]< 10%1 study (1/-)100.0 %NAnot evaluable non important-
Peripheral neuropathy AE (grade 3-4) 0.07 [0.00, 1.18]< 10%1 study (1/-)96.6 %NAnot evaluable non important-
Peripheral oedema AE (grade 3-4) 0.32 [0.03, 3.04]< 10%1 study (1/-)83.9 %NAnot evaluable non important-
Pyrexia AE (grade 3-4) 0.95 [0.06, 15.21]< 10%1 study (1/-)51.5 %NAnot evaluable non important-
Stomatitis AE (grade 3-4) 0.08 [0.01, 0.66]< 10%1 study (1/-)99.1 %NAnot evaluable non important-
Vomiting AE (grade 3-4) 0.47 [0.09, 2.59]< 10%1 study (1/-)80.5 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons